Novo's 19.7% Weight Loss Drug Sounds Great, Until You See the Scoreboard

Lilly's retatrutide, which also hits GLP-1, GIP, and glucagon (the same triple threat as UBT251), posted 28.7% weight loss at 68 weeks in its Phase 3 TRIUMPH-4 trial. That's a staggering number. Even tirzepatide, Lilly's already-approved dual agonist sold as Zepbound, hit around 20.9% at 72 weeks.

Now, comparing 24-week data to 68- or 72-week data is apples-to-oranges. UBT251 could theoretically close the gap as its trial matures. But it's like being down 14 points at halftime and saying, "Well, we still have two quarters left." Technically true. But you'd rather not be in that position.

And retatrutide has multiple Phase 3 readouts coming in 2026, with potential for losses exceeding 30% in longer-duration trials. If those numbers hold, Novo's triple agonist won't just be behind; it'll be playing a different sport.

The CagriSema Hangover

To understand why UBT251's timing matters, you need to rewind 24 hours. CagriSema was supposed to be Novo's answer to Zepbound. The REDEFINE 4 trial pitted CagriSema directly against tirzepatide over 84 weeks. The result: 23% weight loss for CagriSema versus 25.5% for tirzepatide.

That 2.5-percentage-point gap doesn't sound huge. But the trial's goal was to prove CagriSema was at least as good as tirzepatide, what scientists call "non-inferiority." It failed that test. In the pharma world, that's like showing up to a spelling bee and misspelling your own name. You didn't just lose; you lost on the one thing you were specifically trying to prove.

Novo's Chief Scientific Officer, Martin Holst Lange, attributed the miss to tirzepatide performing better than expected in this patient population. He emphasized that 23% weight loss is still clinically meaningful and that the company remains confident in its broader pipeline.

Fair point. But Wall Street wasn't buying the optimism. A 15% stock drop says more than any earnings call ever could.

The $2 Billion Bet

Novo licensed UBT251 from United Laboratories in March 2025 for $200 million upfront and up to $1.8 billion in milestone payments. United Laboratories keeps the rights in China (including Hong Kong, Macau, and Taiwan), while Novo gets the rest of the world.

The deal structure tells you something about Novo's mindset. They're diversifying aggressively. CagriSema is still heading toward a potential FDA approval decision in late 2026, based on earlier REDEFINE 1 and 2 data. Amycretin, Novo's amylin/GLP-1 combo, enters Phase 3 this year. A higher-dose Wegovy (7.2 mg) is awaiting FDA review. And now UBT251 slots in as yet another card in the deck.

It's the biotech equivalent of a basketball team that keeps drafting point guards. At some point, one of them has to work out, right?

What Comes Next

United Laboratories plans to launch a Phase 3 trial in China for UBT251 in obesity, targeting a 2028 launch in that market. Meanwhile, Novo has kicked off a global Phase 1b/2a trial with roughly 330 participants, with results expected in 2027. A Phase 2 trial in type 2 diabetes is planned for the second half of 2026.

The real moment of truth comes when Novo's global trial data arrives. The China results are encouraging, but different patient populations, dosing protocols, and trial designs could produce different numbers. And by 2027, Lilly's retatrutide could already be on the market or deep into regulatory review with data that makes today's results look quaint.

The Bigger Picture

Novo Nordisk essentially invented the modern obesity drug market. Wegovy changed the conversation about weight loss forever. But pioneering a category and dominating it long-term are two very different things; just ask BlackBerry.

Lilly now has the better-performing approved drug (tirzepatide), a potentially dominant triple agonist in the pipeline (retatrutide), and even an oral option in orforglipron nearing an FDA decision. Novo is scrambling to close a gap it didn't expect to open.

UBT251 at 19.7% in 24 weeks is a real result with real promise. It's not a failure by any stretch. But in a race where the finish line keeps moving further out, where 25% might soon become 30%, "pretty good" isn't the same as "good enough."

Novo needs UBT251 to be more than a consolation prize dropped the day after a loss. It needs it to be a comeback story. The next few years will tell us which one it is.

The Cancer Drug That Plays Dead Until It Finds Its Target

Astellas just dropped $335 million upfront on a cancer drug that stays completely dormant until it reaches the tumor; then it wakes up and attacks. The early data on VIR-5500 is turning heads, and the deal's timing tells you everything about Astellas' post-XTANDI anxiety.